An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Behcet's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Janssen Biotech
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 8 Jul 2018.
- 31 Oct 2017 Planned number of patients changed from 37 to 31.